ATE511392T1 - Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit - Google Patents

Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Info

Publication number
ATE511392T1
ATE511392T1 AT08727550T AT08727550T ATE511392T1 AT E511392 T1 ATE511392 T1 AT E511392T1 AT 08727550 T AT08727550 T AT 08727550T AT 08727550 T AT08727550 T AT 08727550T AT E511392 T1 ATE511392 T1 AT E511392T1
Authority
AT
Austria
Prior art keywords
dosage forms
baclofen
methods
oral dosage
prodrug
Prior art date
Application number
AT08727550T
Other languages
English (en)
Inventor
David Kidney
Kenneth Cundy
Srikonda Sastry
Manshiu Leung
Original Assignee
Xenoport Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenoport Inc filed Critical Xenoport Inc
Application granted granted Critical
Publication of ATE511392T1 publication Critical patent/ATE511392T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08727550T 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit ATE511392T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88459807P 2007-01-11 2007-01-11
PCT/US2008/050796 WO2008086492A1 (en) 2007-01-11 2008-01-10 Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment

Publications (1)

Publication Number Publication Date
ATE511392T1 true ATE511392T1 (de) 2011-06-15

Family

ID=39432550

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08727550T ATE511392T1 (de) 2007-01-11 2008-01-10 Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit

Country Status (8)

Country Link
US (1) US20080206332A1 (de)
EP (1) EP2117517B1 (de)
JP (1) JP2010515754A (de)
AT (1) ATE511392T1 (de)
CA (1) CA2674610C (de)
ES (1) ES2365574T3 (de)
TW (1) TWI369982B (de)
WO (1) WO2008086492A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1670451A4 (de) * 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
US8795725B2 (en) 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
TW200936123A (en) * 2007-11-06 2009-09-01 Xenoport Inc Use of prodrugs of GABAb agonists for treating neuropathic and musculoskeletal pain
EP2065038A1 (de) 2007-11-30 2009-06-03 Pharnext Neue therapeutische Ansätze zur Behandlung der Charcot-Marie-Tooth Krankheit
WO2010064139A2 (en) * 2008-12-04 2010-06-10 Intec Pharma Ltd. Zaleplon gastroretentive drug delivery system
NZ594648A (en) * 2009-03-03 2013-12-20 Xenoport Inc Sustained release oral dosage forms of an r-baclofen prodrug
CA2758245A1 (en) * 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
US9393241B2 (en) * 2009-06-02 2016-07-19 Pharnext Compositions for treating CMT and related disorders
EP2263665A1 (de) 2009-06-02 2010-12-22 Pharnext Neue Zusammensetzungen zur Behandlung von CMT und verwandten Erkrankungen
US20110071630A1 (en) * 2009-09-10 2011-03-24 Boston Foundation For Sight Sodium channel blocker delivery system with scleral lens
PH12012500886A1 (en) 2009-11-03 2012-11-26 Lupin Ltd Modified release formulation of lacosamide
WO2011079074A1 (en) * 2009-12-24 2011-06-30 Acura Phamaceuticals, Inc. Pharmaceutical compositions for deterring misuse, abuse, and diversion
US20110200671A1 (en) 2010-02-17 2011-08-18 Sun Pharma Advanced Research Company Ltd. Method of treating a disease condition susceptible to baclofen therapy
WO2011101863A2 (en) * 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
WO2011109403A1 (en) 2010-03-01 2011-09-09 Xenoport, Inc. Use of (3r)-4-{[(1s)-2-methyl-1- (2-methylpropanoyloxy)propoxy]carbonylamino}-3-(4-chlorophenyl) butanoic acid for treating urinary incontinence
US20130251813A1 (en) * 2010-12-02 2013-09-26 Ucb Pharma Gmbh Formulation of lacosamide
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
US9248111B2 (en) 2011-03-01 2016-02-02 Pharnext Therapeutic approaches for treating parkinson's disease
EP2705842A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Morbus Parkinson
UA115968C2 (uk) 2011-03-01 2018-01-25 Фарнекст Нові композиції для лікування неврологічних захворювань
RS57426B1 (sr) 2011-03-01 2018-09-28 Pharnext Terapija neuroloških poremećaja kombinacijom baklofena i akamprosata
WO2013023155A1 (en) 2011-08-11 2013-02-14 Xenoport, Inc. Anhydrous and hemihydrate crystalline forms of an (r)-baclofen prodrug, methods of synthesis and methods of use
US9180108B2 (en) 2011-10-27 2015-11-10 Medtronic, Inc. Baclofen formulations and methods for making same
CA2874737A1 (en) * 2012-06-01 2013-12-05 Lynn Health Science Institute, Inc. Use of baclofen to treat insomnia
US9545389B2 (en) 2012-07-18 2017-01-17 Pharnext Baclofen and acamprosate based therapy of macular degeneration disorders
EP2705843A1 (de) 2012-09-05 2014-03-12 Pharnext Therapeutische Ansätze zur Behandlung von Epilepsie und zugehöriger Erkrankungen durch Reduzierung der Epileptogenese
EP2705841A1 (de) 2012-09-05 2014-03-12 Pharnext Kombinierungen aus Nootropikagenten zur Behandlung von kognitiven Dysfunktionen
EP2968178B1 (de) 2013-03-15 2019-10-09 Inspirion Delivery Sciences LLC Arzneimittel mit einer ph-abhängigen komponente und einem ph-erhöhenden mittel
HUE040023T2 (hu) 2013-06-05 2019-02-28 Pharnext Stabil orális oldatok kombinált API-hoz
AU2015217796B2 (en) 2014-02-11 2020-04-30 Pharnext Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
WO2016132233A1 (en) 2015-02-20 2016-08-25 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release oral dosage form of gaba receptor agonist with enhanced pharmacokinetics
US10987328B2 (en) 2015-02-20 2021-04-27 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10300032B2 (en) 2015-02-20 2019-05-28 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form
US10172800B2 (en) 2015-02-20 2019-01-08 Osmotica Kereskedelmi Es Szolgaltato Kft Controlled release dosage form with enhanced pharmacokinetics
EP3397253A1 (de) 2015-12-30 2018-11-07 Adamas Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur behandlung von erkrankungen im zusammenhang mit krämpfen
WO2017134280A1 (en) * 2016-02-05 2017-08-10 Pharnext Novel combinatorial therapies of neurological disorders
US10383870B2 (en) 2016-06-10 2019-08-20 Pharnext Early treatment of CMT disease
US10736876B2 (en) 2017-04-24 2020-08-11 Pharnext Idalopirdine-based combinatorial therapies of Alzheimer's disease
EP3697779B1 (de) 2017-10-20 2025-03-05 Eagle Research Labs Limited Dantrolen-prodrugs und verfahren zu ihrer verwendung
EP3746062A1 (de) 2018-01-29 2020-12-09 Pharnext Baclofen- und acamprosat-basierte therapie der alzheimer-krankheit bei patienten, die nicht mehr auf die acetylcholinesterase-inhibitor-therapie ansprechen
ES2953059T3 (es) 2019-07-03 2023-11-07 Alvogen Inc Comprimidos de liberación controlada de pregabalina, método de fabricación, y método de uso de los mismos

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
US5006560A (en) * 1989-12-20 1991-04-09 Schering Corporation Use of GABA-B selective agonists as anti-tussive agents
GB9308430D0 (en) * 1993-04-23 1993-06-09 Glaxo Group Ltd Medicaments
SE9603408D0 (sv) * 1996-09-18 1996-09-18 Astra Ab Medical use
EP1343805A4 (de) * 2000-10-06 2005-07-20 Xenoport Inc Von gallensäuren abgeleitete verbindungen für die bereitstellung anhaltender systemischer konzentrationen von arzneimitteln nach oraler verabreichung
US6818787B2 (en) * 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) * 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) * 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7232924B2 (en) * 2001-06-11 2007-06-19 Xenoport, Inc. Methods for synthesis of acyloxyalkyl derivatives of GABA analogs
DE60208065T2 (de) * 2001-08-09 2006-07-13 Eli Lilly And Co., Indianapolis Cyclohept'b! indolderivate als spla2-inhibitoren
AU2002316231A1 (en) * 2002-02-19 2003-09-29 Xenoport, Inc. Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof
MXPA05010515A (es) * 2003-03-31 2006-03-10 Xenoport Inc Tratamiento o prevencion de sofocos calientes utilizando profarmacos de analogos de gaba.
US7662987B2 (en) * 2003-07-15 2010-02-16 Xenoport, Inc. Methods for synthesis of acyloxyalkyl compounds
KR101140559B1 (ko) * 2003-08-20 2012-07-05 제노포트 인코포레이티드 아실옥시알킬 카르바메이트 프로드러그, 합성 및 사용 방법
EP1670451A4 (de) * 2003-09-11 2009-10-21 Xenoport Inc Behandlung und/oder prävention von harninkontinenz mit prodrugs von gaba-analoga
WO2005027850A2 (en) * 2003-09-17 2005-03-31 Xenoport, Inc. Treating or preventing restless legs syndrome using prodrugs of gaba analogs
KR101096480B1 (ko) * 2003-10-14 2011-12-20 제노포트 인코포레이티드 감마-아미노부티르산 유사체의 결정질 형태
DK1716115T3 (da) * 2003-12-30 2013-05-27 Xenoport Inc Syntese af acyloxyalkylcarbamat-prodrug og mellemprodukter deraf
MXPA06011322A (es) * 2004-04-02 2007-02-21 Impax Laboratories Inc Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
US8795725B2 (en) * 2004-11-04 2014-08-05 Xenoport, Inc. GABA analog prodrug sustained release oral dosage forms
WO2008011016A2 (en) * 2006-07-18 2008-01-24 Dynogen Pharmaceuticals, Inc. Treating gastroesophageal reflux disease with 5-ht3- and gaba receptor agonists
MX2009005114A (es) * 2006-11-14 2009-07-16 Xenoport Inc Uso de los profarmacos gabapentina y pregabalina para tratar el tinnitus.
EA200970487A1 (ru) * 2006-12-08 2009-12-30 Ксенопорт, Инк. Применение пролекарств аналогов гамк для лечения заболеваний

Also Published As

Publication number Publication date
WO2008086492A1 (en) 2008-07-17
EP2117517A1 (de) 2009-11-18
US20080206332A1 (en) 2008-08-28
TW200900054A (en) 2009-01-01
JP2010515754A (ja) 2010-05-13
TWI369982B (en) 2012-08-11
EP2117517B1 (de) 2011-06-01
ES2365574T3 (es) 2011-10-07
CA2674610A1 (en) 2008-07-17
CA2674610C (en) 2013-06-18

Similar Documents

Publication Publication Date Title
ATE511392T1 (de) Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
CY1121593T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
CR20210368A (es) Combinación de dextrometorfano y bupropión para el tratamiento de depresión
MX374396B (es) Rocio de fentanilo sublingual.
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
DK2324008T3 (da) Diarylpyrazol som protein kinase inhibitorer
EA201490949A1 (ru) Ингибиторы киназ
CY1114139T1 (el) Πλακιδιο βουπρενορφινης για τη θεραπεια υποκαταστασης ναρκωτικων
UY32487A (es) Composiciones farmacéuticas de liberación inmediata comprendiendo oxicodona y naloxona
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
EA200870254A1 (ru) Способ лечения воспалительных заболеваний
MX2010002735A (es) Envase de titulacion para neramexano y su uso en el tratamiento de un trastorno del oido interno.
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CY1115381T1 (el) Διενυδρη υδροχλωρικη ναλμεφαινη
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
HN2012000023A (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
WO2011056240A3 (en) Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
EA200970483A1 (ru) Применение пролекарств габапентина и прегабалина для лечения шума в ушах
AR062401A1 (es) Uso de derivados del 2,5-dihidroxibenceno para tratar dermatitis
CY1112770T1 (el) Αναστολεις κινασης και μεθοδοι χρησης τους
MX2019006721A (es) Tratamiento para la colangitis biliar primaria.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties